Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials Ben Hargreaves biologic medicines, China, fda, Lilly 0 Comment China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates Share X FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials https://pharmaphorum.com/market-access-2/fdas-treatment-of-china-developed-drugs-spurs-demands/
